scholarly journals Microwave-Synthesized Platinum-Embedded Mesoporous Silica Nanoparticles as Dual-Modality Contrast Agents: Computed Tomography and Optical Imaging

2019 ◽  
Vol 20 (7) ◽  
pp. 1560 ◽  
Author(s):  
Chia-Hui Chu ◽  
Shih-Hsun Cheng ◽  
Nai-Tzu Chen ◽  
Wei-Neng Liao ◽  
Leu-Wei Lo
Keyword(s):  
Computed Tomography ◽  
Mesoporous Silica ◽  
Contrast Agents ◽  
Optical Imaging ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Particle Diameter ◽  
Ct Imaging ◽  
Average Particle ◽  
Dual Modality

Nanoparticle-based imaging contrast agents have drawn tremendous attention especially in multi-modality imaging. In this study, we developed mesoporous silica nanoparticles (MSNs) for use as dual-modality contrast agents for computed tomography (CT) and near-infrared (NIR) optical imaging (OI). A microwave synthesis for preparing naked platinum nanoparticles (nPtNPs) on MSNs (MSNs-Pt) was developed and characterized with physicochemical analysis and imaging systems. The high density of nPtNPs on the surface of the MSNs could greatly enhance the CT contrast. Inductively coupled plasma mass spectrometry (ICP-MS) revealed the MSNs-Pt compositions to be ~14% Pt by weight and TEM revealed an average particle diameter of ~50 nm and covered with ~3 nm diameter nPtNPs. To enhance the OI contrast, the NIR fluorescent dye Dy800 was conjugated to the MSNs-Pt nanochannels. The fluorescence spectra of MSNs-Pt-Dy800 were very similar to unconjugated Dy800. The CT imaging demonstrated that even modest degrees of Pt labeling could result in substantial X-ray attenuation. In vivo imaging of breast tumor-bearing mice treated with PEGylated MSNs-Pt-Dy800 (PEG-MSNs-Pt-Dy800) showed significantly improved contrasts in both fluorescence and CT imaging and the signal intensity within the tumor retained for 24 h post-injection.

scholarly journals Shortwave Infrared Imaging with J-Aggregates Stabilized in Hollow Mesoporous Silica Nanoparticles

2018 ◽  
Author(s):  
Wei Chen ◽  
ChiAn Cheng ◽  
Emily Cosco ◽  
Shyam Ramakrishnan ◽  
Jakob Lingg ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Contrast Agents ◽  
Silica Nanoparticles ◽  
Near Infrared ◽  
Infrared Imaging ◽  
Mesoporous Silica Nanoparticles ◽  
J Aggregates ◽  
Hollow Mesoporous Silica ◽  
Shortwave Infrared

Tissue is translucent to shortwave infrared (SWIR) light, rendering optical imaging superior in this region. However, the widespread use of optical SWIR imaging has been limited, in part, by the lack of bright, biocompatible contrast agents that absorb and emit light above 1000 nm. J-aggregation offers a means to transform stable, near-infrared (NIR) fluorophores into red-shifted SWIR contrast agents. Here we demonstrate that hollow mesoporous silica nanoparticles (HMSNs) can template the J-aggregation of NIR fluorophore IR-140 to result in nanomaterials that absorb and emit SWIR light. The J-aggregates inside PEGylated HMSNs are stable for multiple weeks in buffer and enable high resolution imaging <i>in vivo</i>with 980 nm excitation.

scholarly journals Facile Fabrication of BiF3: Ln (Ln = Gd, Yb, Er)@PVP Nanoparticles for High-Efficiency Computed Tomography Imaging

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Jun Xie ◽  
Zonglang Zhou ◽  
Sihan Ma ◽  
Xian Luo ◽  
Jiajing Liu ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Oral Administration ◽  
Contrast Agent ◽  
Contrast Agents ◽  
Ct Imaging ◽  
Average Particle ◽  
Gi Tract ◽  
X Ray ◽  
Ct Value ◽  
Ct Contrast

AbstractX-ray computed tomography (CT) has been widely used in clinical practice, and contrast agents such as Iohexol are often used to enhance the contrast of CT imaging between normal and diseased tissue. However, such contrast agents can have some toxicity. Thus, new CT contrast agents are urgently needed. Owing to the high atomic number (Z = 83), low cost, good biological safety, and great X-ray attenuation property (5.74 cm2 kg−1 at 100 keV), bismuth has gained great interest from researchers in the field of nano-sized CT contrast agents. Here, we synthesized BiF3: Ln@PVP nanoparticles (NPs) with an average particle size of about 380 nm. After coating them with polyvinylpyrrolidone (PVP), the BiF3: Ln@PVP NPs possessed good stability and great biocompatibility. Meanwhile, compared with the clinical contrast agent Iohexol, BiF3: Ln@PVP NPs showed superior in vitro CT imaging contrast. Subsequently, after in situ injection with BiF3: Ln@PVP NPs, the CT value of the tumor site after the injection was significantly higher than that before the injection (the CT value of the pre-injection and post-injection was 48.9 HU and 194.58 HU, respectively). The morphology of the gastrointestinal (GI) tract can be clearly observed over time after oral administration of BiF3: Ln@PVP NPs. Finally, the BiF3: Ln@PVP NPs were completely discharged from the GI tract of mice within 48 h of oral administration with no obvious damage to the GI tract. In summary, our easily synthesized BiF3: Ln@PVP NPs can be used as a potential clinical contrast agent and may have broad application prospects in CT imaging.

scholarly journals Stable Encapsulation of Air in Mesoporous Silica Nanoparticles: Fluorocarbon-Free Nanoscale Ultrasound Contrast Agents

2016 ◽  
Vol 5 (11) ◽  
pp. 1290-1298 ◽  
Author(s):  
Adem Yildirim ◽  
Rajarshi Chattaraj ◽  
Nicholas T. Blum ◽  
Galen M. Goldscheitter ◽  
Andrew P. Goodwin
Keyword(s):  
Mesoporous Silica ◽  
Contrast Agents ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Ultrasound Contrast Agents ◽  
Ultrasound Contrast

Optimized Rhodamine B labeled mesoporous silica nanoparticles as fluorescent scaffolds for the immobilization of photosensitizers: a theranostic platform for optical imaging and photodynamic therapy

2016 ◽  
Vol 18 (13) ◽  
pp. 9042-9052 ◽  
Author(s):  
B. Martins Estevão ◽  
I. Miletto ◽  
L. Marchese ◽  
E. Gianotti
Keyword(s):  
Photodynamic Therapy ◽  
Mesoporous Silica ◽  
Contrast Agent ◽  
Optical Imaging ◽  
Silica Nanoparticles ◽  
Rhodamine B ◽  
Mesoporous Silica Nanoparticles

A theranostic nanoplatform coupling optical-imaging with photodynamic-therapy was prepared by using Rhodamine B as a contrast agent and verteporfin as a photosensitizer.

Sign in / Sign up

Export Citation Format

Share Document